The SARAH Study

The SARAH study (SorAfenib versus Radioembolisation in Advanced Hepatocellular carcinoma) is a Phase III, open-label randomised controlled trial in locally advanced or inoperable Hepatocellular Carcinoma (HCC).

SARAH was an investigator study sponsored by Assistance Publique – Hôpitaux de Paris (AP-HP) and supported by Sirtex Medical Limited.

The SARAH study was launched in December 2011 and concluded enrolment in February 2015.

SARAH Study Design

SARAH was designed to directly compare the efficacy and safety of SIR-Spheres® Y-90 resin microspheres with sorafenib, a systemic treatment, currently the standard of care in advanced hepatocellular carcinoma.

With 459 patients treated in 25 clinical centres across France, SARAH is the largest randomised study ever to compare Selective Internal Radiation Therapy (SIRT) - or any liver-directed therapy - against the standard-of-care systemic therapy in the treatment of primary liver cancer.

Now leaving

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.



You are now leaving your current region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.



This content is intended for healthcare professionals only

By clicking "Yes" you are confirming that you are a healthcare professional. If you are not a healthcare professional, then please click "Go to Homepage" which will direct you to the Sirtex homepage.

Yes Go to Homepage